David Roblin Selected Research

pegcantratinib

1/2018	Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.
5/2015	Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Roblin Research Topics

Disease

1	Neoplasms (Cancer) 01/2018
1	Clostridium Infections 01/2017
1	Infections 01/2017
1	Pruritus (Itching) 05/2015
1	Psoriasis (Pustulosis Palmaris et Plantaris) 05/2015
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2002
1	Heart Failure 12/2002
1	Pulmonary Hypertension 12/2002
1	Erectile Dysfunction 12/2002
1	Myocardial Ischemia (Ischemic Heart Diseases) 12/2002

Drug/Important Bio-Agent (IBA)

2	Pharmaceutical PreparationsIBA 01/2018 - 01/2017
2	pegcantratinibIBA 01/2018 - 05/2015
2	TropomyosinIBA 01/2018 - 05/2015
2	Phosphotransferases (Kinase)IBA 01/2018 - 05/2015
1	ridinilazoleIBA 01/2017
1	Vancomycin FDA LinkGeneric 01/2017
1	Capsaicin (Zostrix)FDA Link 05/2015
1	CalciumIBA 05/2015
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 12/2002
1	Sildenafil Citrate (Viagra)FDA Link 12/2002
1	Phosphodiesterase 5 InhibitorsIBA 12/2002
1	Guanosine Monophosphate (5' Guanylic Acid)IBA 12/2002
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2002

Therapy/Procedure

1	Therapeutics 05/2015